-

Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan

  • First blood-only liquid biopsy test for minimal residual disease now covered for patients with stage II or III colorectal cancer
  • Test used after surgery or curative treatment to inform physician decisions about adjuvant therapy and to monitor for disease progression, recurrence or relapse

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing.

Geisinger is providing coverage for the Guardant Reveal test for individuals with stage II or III colorectal cancer after curative treatment (including surgery) to inform physician decisions about post-treatment therapy and to monitor for disease progression, recurrence or relapse. The frequency of testing covered is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer. It includes the initial ctDNA test 4 to 6 weeks after surgery (or 2 to 4 weeks after completion of systemic therapy) and thereafter every 3 to 6 months for the first two years, and every 6 to 12 months for the following 3 years.

“We are pleased that Geisinger Health Plan has taken this important step to make blood testing for residual disease more accessible to its members,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “This decision will help oncologists make more informed decisions about treatment and monitoring for colorectal cancer patients and survivors, to help improve their outcomes.”

Minimal residual disease refers to a subclinical measure of cancer burden that remains during and following treatment. A patient’s MRD status is a reliable indicator of clinical outcome and response to therapy and can be used for risk stratification and to guide treatment options when used in conjunction with other clinical data.

The Geisinger Health Plan provides coverage for more than half a million members. This policy decision adds to the payor coverage of Guardant Reveal, which received Medicare coverage in August 2022 and additional commercial payor coverage in July 2023.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY® tests for advanced stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).

Contacts

Investor Contact:
investors@guardanthealth.com

Media Contact:
Michael Weist
press@guardanthealth.com
+1 650-647-3643

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
investors@guardanthealth.com

Media Contact:
Michael Weist
press@guardanthealth.com
+1 650-647-3643

More News From Guardant Health, Inc.

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago. Key data that will be highlighted include: An oral presentation...

Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant’s portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinics in Canada. Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding Quebec), and the agre...

Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare...
Back to Newsroom